Strides Arcolab is currently trading at Rs. 1226.70, up by 24.35 points or 2.03% from its previous closing of Rs. 1202.35 on the BSE.
The scrip opened at Rs. 1205.00 and has touched a high and low of Rs. 1227.05 and Rs. 1202.15 respectively. So far 29419 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1249.00 on 08-Apr-2015 and a 52 week low of Rs. 448.50 on 16-Apr-2014.
Last one week high and low of the scrip stood at Rs. 1249.00 and Rs. 1170.00 respectively. The current market cap of the company is Rs. 7216.47 crore.
The promoters holding in the company stood at 27.67% while Institutions and Non-Institutions held 46.39% and 25.93% respectively.
Strides Arcolab has received approval from the United States Food & Drug Administration (USFDA) for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate, and Potassium Chloride for Oral Solution, 420 grams/11.2 grams/5.72 grams/1.48 grams/4 Liters. According to IMS data, the US market for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate, and Potassium Chloride for Oral Solution is approximately USD 20 Million.
The product will be manufactured at the Company's Oral dosage facility at Bangalore and marketed by Strides in the US Market. It is used for bowel cleansing prior to colonoscopy. Polyethylene glycol 3350 is an osmotic laxative, and along with the electrolytes, the combination is used in preparation for colonoscopy in adults and pediatric patients aged six months or greater.
Strides Arcolab is a global pharmaceutical company headquartered
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: